Iraj Golzari, MD
General Practice · Venice, FLNPI 1689754426
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $747 of the $847 with a category attached, or 88.2%. It is spread thinly across 12 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $343 and has fallen 94.8% since, to $18 in 2025.
Across 46 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$190
- Astellas Pharma US Inc$134
- GSK$108
- AbbVie$101
- Lilly USA, LLC$88
- AstraZeneca$82
- plus $145 from 6 others
What the payments were for
- Food & beverage$74788%
- Education$10012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $190 |
| Astellas Pharma US Inc | 3 | $134 |
| GSK | 7 | $108 |
| AbbVie(2 entities) | 7 | $101 |
| Lilly USA, LLC | 5 | $88 |
| AstraZeneca | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Novo Nordisk | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Amgen | 1 | $13 |
| Genentech USA, Inc. | 1 | $11 |
How this compares
$847 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 80 | $106,608 |
| OzempicSemaglutide | 64 | $88,223 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $86,461 |
| TrulicityDulaglutide | 17 | $37,058 |
| JanuviaSitagliptin Phosphate | 32 | $36,627 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $33,939 |
| FarxigaDapagliflozin Propanediol | 17 | $21,667 |
| MyrbetriqMirabegron | 32 | $20,577 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $20,340 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $19,061 |
| XareltoRivaroxaban | 20 | $18,915 |
| JardianceEmpagliflozin | 13 | $14,639 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $13,641 |
| LinzessLinaclotide | 20 | $12,751 |
| TradjentaLinagliptin | 11 | $12,330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $108 | $120,400162 claims |
| PfizerEliquis | $190 | $106,60880 claims |
| Novo NordiskOzempic | $39 | $88,22364 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $82 | $44,96157 claims |
| Lilly USA, LLCTrulicity | $88 | $37,05817 claims |
| Astellas Pharma US IncMyrbetriq | $134 | $20,57732 claims |
| AbbVieLinzess, Synthroid | $101 | $14,81269 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $39 | $7,39213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.
Other general practice in Venice
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Sarah JockinTampa$308K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
- Florencia ZiemkeWest Palm Beach$208K
- Ausberto HidalgoPembroke Pines$171K
- Rickie FergusonPembroke Pines$170K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.